Page 603 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 38 Heme Biosynthesis and Its Disorders 513.e5

194. Riley LG, Cooper S, Hickey P, et al: Mutation of the mitochondrial 216. Gale RE, Wheadon H, Goldstone AH, et al: Frequency of clonal remis-
tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, sion in acute myeloid leukaemia. Lancet 341:138, 1993.
and sideroblastic anemia–MLASA syndrome. Am J Hum Genet 87:52, 217. Kampmeier P, Anastasi J, Vardiman JW: Issues in the pathology of
2010. the myelodysplastic syndromes. Hematol Oncol Clin North Am 6:501,
195. Taylor RW, Pyle A, Griffin H, et al: Use of whole-exome sequencing to 1992.
determine the genetic basis of multiple mitochondrial respiratory chain 218. Germing U, Strupp C, Kuendgen A, et al: Prospective validation of the
complex deficiencies. JAMA 312:68, 2014. WHO proposals for the classification of myelodysplastic syndromes.
196. Wiseman DH, May A, Jolles S, et al: A novel syndrome of congenital Haematologica 91:1596, 2006.
sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and 219. Cazzola M, Barosi G, Gobbi PG, et al: Natural history of idiopathic
developmental delay (SIFD). Blood 122:112, 2013. refractory sideroblastic anemia. Blood 71:305, 1988.
197. Chakraborty PK, Schmitz-Abe K, Kennedy EK, et al: Mutations in 220. Gattermann N, Aul C, Schneider W: Two types of acquired idiopathic
TRNT1 cause congenital sideroblastic anemia with immunodeficiency, sideroblastic anaemia (AISA). Br J Haematol 74:45, 1990.
fevers, and developmental delay (SIFD). Blood 124:2867, 2014. 221. May SJ, Smith SA, Jacobs A, et al: The myelodysplastic syndrome:
198. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the clas- analysis of laboratory characteristics in relation to the FAB classification.
sification of the myelodysplastic syndromes. Br J Haematol 51:189, Br J Haematol 59:311, 1985.
1982. 222. Clatch RJ, Krigman HR, Peters MG, et al: Dysplastic haemopoiesis
199. Swerdlow SH, Campo E, Harris NL, et al: Classification of Tumours of following orthotopic liver transplantation: comparison with similar
Haematopoietic and Lymphoid Tissues, Geneva, 2008, WHO Press. changes in HIV infection and primary myelodysplasia. Br J Haematol
200. Kushner JP, Lee GR, Wintrobe MM, et al: Idiopathic refractory sidero- 88:685, 1994.
blastic anemia: clinical and laboratory investigation of 17 patients and 223. Tricot G, De Wolf-Peeters C, Hendrickx B, et al: Bone marrow
review of the literature. Medicine (Baltimore) 50:139, 1971. histology in myelodysplastic syndromes. I. Histological findings in
201. Reilly JT, Dolan G: Proposed classification for the myelodysplasia/ myelodysplastic syndromes and comparison with bone marrow smears.
myelofibrosis syndromes. Br J Haematol 79:653, 1991. Br J Haematol 57:423, 1984.
202. Szpurka H, Tiu R, Murugesan G, et al: Refractory anemia with ringed 224. Malcovati L, Porta MG, Pascutto C, et al: Prognostic factors and life
sideroblasts associated with marked thrombocytosis (RARS-T), another expectancy in myelodysplastic syndromes classified according to WHO
myeloproliferative condition characterized by JAK2 V617F mutation. criteria: a basis for clinical decision making. J Clin Oncol 23:7594,
Blood 108:2173, 2006. 2005.
203. Raskind WH, Tirumali N, Jacobson R, et al: Evidence for a multistep 225. Juneja SK, Imbert M, Sigaux F, et al: Prevalence and distribution of
pathogenesis of a myelodysplastic syndrome. Blood 63:1318, 1984. ringed sideroblasts in primary myelodysplastic syndromes. J Clin Pathol
204. Young NS: The problem of clonality in aplastic anemia: Dr Dameshek’s 36:566, 1983.
riddle, restated. Blood 79:1385, 1992. 226. Mufti GJ, Stevens JR, Oscier DG, et al: Myelodysplastic syndromes:
205. Aoki Y: Multiple enzymatic defects in mitochondria in hematological a scoring system with prognostic significance. Br J Haematol 59:425,
cells of patients with primary sideroblastic anemia. J Clin Invest 66:43, 1985.
1980. 227. Vallespi T, Torrabadella M, Julia A, et al: Myelodysplastic syndromes:
206. Gattermann N, Retzlaff S, Wang YL, et al: A heteroplasmic point a study of 101 cases according to the FAB classification. Br J Haematol
mutation of mitochondrial tRNALeu(CUN) in non-lymphoid haemo- 61:83, 1985.
poietic cell lineages from a patient with acquired idiopathic sideroblastic 228. Greenberg P, Cox C, LeBeau MM, et al: International scoring system
anaemia. Br J Haematol 93:845, 1996. for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079,
207. Gattermann N, Retzlaff S, Wang YL, et al: Heteroplasmic point 1997.
mutations of mitochondrial DNA affecting subunit I of cytochrome c 229. Hussein KK, Salem Z, Bottomley SS, et al: Acute leukemia in idio-
oxidase in two patients with acquired idiopathic sideroblastic anemia. pathic sideroblastic anemia: response to combination chemotherapy.
Blood 90:4961, 1997. Blood 59:652, 1982.
208. Wulfert M, Kupper AC, Tapprich C, et al: Analysis of mitochondrial 230. Jonasova A, Neuwirtova R, Cermak J, et al: Cyclosporin A therapy
DNA in 104 patients with myelodysplastic syndromes. Exp Hematol in hypoplastic MDS patients and certain refractory anaemias without
36:577, 2008. hypoplastic bone marrow. Br J Haematol 100:304, 1998.
209. Papaemmanuil E, Cazzola M, Boultwood J, et al: Somatic SF3B1 muta- 231. Steensma DP, Tefferi A: Risk-based management of myelodysplastic
tion in myelodysplasia with ring sideroblasts. N Engl J Med 365:1384, syndrome. Oncology (Williston Park) 21:43, 2007.
2011. 232. Brittenham GM: Iron-chelating therapy for transfusional iron overload.
210. Broseus J, Alpermann T, Wulfert M, et al: Age, JAK2(V617F) and N Engl J Med 364:146, 2011.
SF3B1 mutations are the main predicting factors for survival in 233. Meerpohl JJ, Schell LK, Rucker G, et al: Deferasirox for managing iron
refractory anaemia with ring sideroblasts and marked thrombocytosis. overload in people with myelodysplastic syndrome. Cochrane Database
Leukemia 27:1826, 2013. Syst Rev (10):CD007461, 2014.
211. Nikpour M, Scharenberg C, Liu A, et al: The transporter ABCB7 is 234. Eichner ER, Hillman RS: The evolution of anemia in alcoholic patients.
a mediator of the phenotype of acquired refractory anemia with ring Am J Med 50:218, 1971.
sideroblasts. Leukemia 27:889, 2013. 235. Hines JD: Reversible megaloblastic and sideroblastic marrow abnor-
212. Third MIC Cooperative Study Group: Recommendations for a malities in alcoholic patients. Br J Haematol 16:87, 1969.
morphologic, immunological, and cytogenetics (MIC) working clas- 236. Pierce HI, McGuffin RG, Hillman RS: Clinical studies in alcoholic
sification of the primary and therapy-related myelodysplastic disorders. sideroblastosis. Arch Intern Med 136:283, 1976.
Cancer Genet Cytogenet 32:1988. 237. Savage D, Lindenbaum J: Anemia in alcoholics. Medicine (Baltimore)
213. Neuman WL, Rubin CM, Rios RB, et al: Chromosomal loss and dele- 65:322, 1986.
tion are the most common mechanisms for loss of heterozygosity from 238. Hines JD, Cowan DH: Studies on the pathogenesis of alcohol-induced
chromosomes 5 and 7 in malignant myeloid disorders. Blood 79:1501, sideroblastic bone-marrow abnormalities. N Engl J Med 283:441, 1970.
1992. 239. Vech RL, Lumeng L, Li TK: Vitamin B6 metabolism in chronic alcohol
214. Pedersen-Bjergaard J, Pedersen M, Roulston D, et al: Different genetic abuse The effect of ethanol oxidation on hepatic pyridoxal 5’-phosphate
pathways in leukemogenesis for patients presenting with therapy-related metabolism. J Clin Invest 55:1026, 1975.
myelodysplasia and therapy-related acute myeloid leukemia. Blood 240. McColl KE, Moore MR, Thompson GG, et al: Abnormal haem
86:3542, 1995. biosynthesis in chronic alcoholics. Eur J Clin Invest 11:461, 1981.
215. Golomb HM, Alimena G, Rowley JD, et al: Correlation of occupation 241. McColl KE, Thompson GG, Moore MR, et al: Acute ethanol ingestion
and karyotype in adults with acute nonlymphocytic leukemia. Blood and haem biosynthesis in healthy subjects. Eur J Clin Invest 10:107,
60:404, 1982. 1980.